Results 281 to 290 of about 111,447 (309)

Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 701-710, January 2026.
Abstract Aims To analyse prescribing trends in antidiabetic agents stratified by background characteristics among individuals with type 2 diabetes. Materials and Methods This retrospective study used a large‐scale database between 2015 and 2024 in Japan.
Kazuki Aoyama   +14 more
wiley   +1 more source

Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 728-740, January 2026.
Abstract Aims This study aimed to evaluate the efficacy and safety of triple therapy with lobeglitazone 0.5 mg as an add‐on treatment compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin.
Da Hea Seo   +8 more
wiley   +1 more source

Molecular imaging in oncology: Current impact and future directions

Ca-A Cancer Journal for Clinicians, 2022
Steven P Rowe, Martin G Pomper
exaly  

Home - About - Disclaimer - Privacy